Showing posts with label Patients. Show all posts
Showing posts with label Patients. Show all posts

Friday, September 9, 2011

To help doctors and patients, researchers are developing a 'vocabulary of pain'

ScienceDaily (July 26, 2011) — All over the world, patients with chronic pain struggle to express how they feel to the doctors and health-care providers who are trying to understand and treat them.See Also:Health & MedicinePain ControlWorkplace HealthFibromyalgiaMind & BrainCaregivingPTSDBrain InjuryReferenceChronic painBack painTension headacheGate control theory of pain

Now, a University at Buffalo psychiatrist is attempting to help patients suffering from chronic pain and their doctors by drawing on ontology, the branch of philosophy concerned with the nature of being or existence.

The research will be discussed during a tutorial he will give at the International Conference on Biomedical Ontology, sponsored by UB, that will be held in Buffalo July 26-30.

"Pain research is very difficult because nothing allows the physician to see the patient's pain directly," says Werner Ceusters, MD, professor of psychiatry in UB's School of Medicine and Biomedical Sciences, and principal investigator on a new National Institutes of Health grant, An Ontology for Pain and Related Disability, Mental Health and Quality of Life.

"The patient has to describe what he or she is feeling."

That is a serious shortcoming, Ceusters says, because each patient's subjective experience of pain is different. Descriptions of pain therefore lack the precision and specificity that is taken for granted with other disorders, where biomarkers or physiological indicators reveal what health-care providers need in order to assess the severity of a particular disorder.

"If we want to more effectively help people suffering from chronic pain, we need to study a population that is consistent, patients who have features in common," Ceusters says. "The problem with pain is, it's very hard to build up a group with the same sort of pain. People don't have the same vocabulary or linguistic capabilities or even the same cultural backgrounds. It's something pain researchers have struggled with for decades," Ceusters says. "We need to develop a vocabulary of pain."

That's where ontology comes in.

"The philosophical definition of ontology is the study of things that exist and how they relate to each other," says Ceusters, who also is director of the Ontology Research Group of UB's New York State Center of Excellence in Bioinformatics and Life Sciences. "I am a person and you are a person so we share something. Suppose I drop dead. What lies on the floor? Is that still a person? If it is no longer a person, is it still the very same thing that was sitting here as a person but now is a corpse?"

Ceusters says that in much the same way, definitions of pain and especially of chronic pain need to be much more precise; ontology provides methods of distinguishing among categories and describing data in uniform and formal ways.

While the philosophical approach to ontology naturally has its roots in ancient Greece, a computational approach to ontology began in the latter part of the 20th century, when computer scientists interested in artificial intelligence wanted to create software programs that perform reasoning they way humans do. To do so, they began to draw on ontology.

"Here at the University at Buffalo, we excel at combining the two approaches; we have a very strong foundation in the philosophical approach to ontology with Barry Smith, who is a pioneer in contemporary ontology, especially related to biomedical applications," says Ceusters, "while we also have a very strong presence in computational approaches, especially to biomedical ontology. These computational approaches allow us to devise systems of communication in which there is a consistent meaning for terms used in different language systems and conceptual frameworks."

With the $793,571 NIH grant, Ceusters and colleagues will study data gathered from thousands of patients in the U.S., the United Kingdom, Sweden, Israel and Germany who suffer from oral and facial pain, including temporomandibular disorder (TMD).

Ceusters will work with his colleagues, including Richard Ohrbach, DDS, PhD, associate professor of oral diagnostic sciences in the UB School of Dental Medicine, to develop an ontology that allows the data to be described in a much more uniform way.

"The goal is to integrate the data together so that we have a large pool of data that will allow us to obtain better insight into the complexity of pain disorders, specifically the assessment of pain disorders and how they impact mental health and a patients' quality of life," Ceusters says.

The grant will build on past work that Ceusters conducted with a grant from the Oishei Foundation related to improving the classification, diagnosis and treatment of psychiatric conditions.

Ceusters, who has degrees in knowledge engineering and information science as well as in neuropsychiatry, says that the current effort grew out of his work on that grant and also from a meeting with pain researchers that he attended in 2009.

"At that meeting, we discussed how we might build an ontology so that it could represent what pain is and how it relates to body parts and their activities and functions," he says. "Our goal is to create a software program that will allow all pain specialists to express themselves in crystal clear terms," he says, "We will create a symptom checklist that can be understood by computers. We have to define the terminology of pain. This can only be solved by the kind of ontology we are doing here at the University at Buffalo."

Email or share this story:

Vitamin D relieves joint, muscle pain for breast cancer patients

ScienceDaily (July 26, 2011) — High-dose vitamin D relieves joint and muscle pain for many breast cancer patients taking estrogen-lowering drugs, according to a new study from Washington University School of Medicine in St. Louis.See Also:Health & MedicineVitaminVitamin DPain ControlOsteoporosisBreast CancerDietary SupplementReferenceCOX-2 inhibitorBreast cancerHysterectomyHormone replacement therapy

The drugs, known as aromatase inhibitors, are commonly prescribed to shrink breast tumors fueled by the hormone estrogen and help prevent cancer recurrence. They are less toxic than chemotherapy, but for many patients, the drugs may cause severe musculoskeletal discomfort, including pain and stiffness in the hands, wrists, knees, hips, lower back, shoulders and feet.

"About half of patients can experience these symptoms," says Antonella L. Rastelli, MD, assistant professor of medicine and first author of the study published online in the journal Breast Cancer Research and Treatment. "We don't know exactly why the pain occurs, but it can be very debilitating -- to the point that patients decide to stop taking aromatase inhibitors."

Because the drugs reduce cancer recurrence, finding a way to help patients stay on them is important for long-term, relapse-free survival, according to Rastelli. Aromatase inhibitors are prescribed to post-menopausal women for at least five years and often longer after a breast cancer diagnosis. There is some evidence that patients who experience the drugs' side effects are less likely to see their cancer return, providing even more incentive to help these patients continue taking them.

It was Rastelli's colleague, Marie E. Taylor, MD, assistant professor of radiation oncology, who first noticed that patients on aromatase inhibitors who experienced this pain found some relief from high doses of vitamin D.

So Rastelli's group recruited 60 patients who reported pain and discomfort associated with anastrozole, one of three FDA-approved aromatase inhibitors. The patients they studied also had low vitamin D levels. Half the group was randomly assigned to receive the recommended daily dose of vitamin D (400 international units) plus a 50,000-unit vitamin D capsule once a week. The other half received the daily dose of 400 units of vitamin D plus a weekly placebo. All subjects received 1,000 milligrams of calcium daily throughout the study.

Patients in the study reported any pain they experienced through three different questionnaires. They were asked to quantify their pain intensity, as well as report how much the pain altered their mood, affected their work and interfered with relationships and daily activities. The results show that patients receiving high-dose vitamin D every week reported significantly less musculoskeletal pain and also were less likely to experience pain that interfered with daily living.

"High-dose vitamin D seems to be really effective in reducing the musculoskeletal pain caused by aromatase inhibitors," Rastelli says. "Patients who get the vitamin D weekly feel better because their pain is reduced and sometimes goes away completely. This makes the drugs much more tolerable. Millions of women worldwide take aromatase inhibitor therapy, and we may have another 'tool' to help them remain on it longer."

Like anastrozole used in this study, the other two FDA-approved aromatase inhibitors, letrozole and exemestane, also cause musculoskeletal pain. Given the similar side effects, Rastelli says patients on these drugs may also benefit from high-dose vitamin D.

The vitamin used in this study is a plant-derived type called vitamin D2. Rastelli says it achieves the best results when given weekly because the body metabolizes it within seven to 10 days. Rastelli and her colleagues did not use high-dose vitamin D3, which remains in the body longer.

"This was a very carefully conducted study, and the placebo control makes the findings quite compelling," says Matthew J. Ellis, MD, PhD, the study's senior author and director of the Breast Cancer Program at the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. "We should follow up these findings further to determine the most efficacious and safe approach to vitamin D supplementation in our breast cancer patients."

Since vitamin D helps the body absorb calcium, too much of it can cause high levels of calcium in the urine, which may increase the risk of kidney stones. Such possible side effects emphasize the importance of tracking patients' urine calcium levels while taking high-dose vitamin D.

"It's important to monitor the patients, but overall it appears to be very safe," Rastelli says. "Because vitamin D2 is eliminated from the body so quickly, it's very hard to overdose."

In addition to relieving pain, the group wanted to examine whether vitamin D could protect against the bone loss often seen in patients taking aromatase inhibitors. The researchers measured each patient's bone density at the beginning of the study and again after six months.

Perhaps because of its role in calcium absorption, high-dose vitamin D did appear to help maintain bone density at the neck of the femur, the top of the thighbone near the hip joint. Although the result did not reach statistical significance, Rastelli calls the result promising and worth further studies.

"It's great that we have something as simple as vitamin D to help patients alleviate some of this pain," Rastelli says. "It's not toxic -- it doesn't cause major side effects. And if it is actually protecting against bone loss, that's even better."

The study was supported by Astra-Zeneca, which makes the aromatase inhibitor anastrozole under the brand name Arimidex.

Email or share this story:

Thursday, September 8, 2011

Concern over intensive treatment for patients with Type 2 diabetes

ScienceDaily (July 26, 2011) — Doctors should be cautious about prescribing intensive glucose lowering treatment for patients with type 2 diabetes as a way of reducing heart complications, concludes a new study published online in the British Medical Journal.See Also:Health & MedicineDiabetesPersonalized MedicineHeart DiseaseCholesterolWounds and HealingToday's HealthcareReferenceDiabetes mellitus type 2Blood sugarDiabetic dietGlycemic index

French researchers found that intensive glucose lowering treatment, which is widely used for people with type 2 diabetes to reduce their heightened risk of cardiovascular disease, showed no benefit on all-cause or cardiovascular mortality.

Globally, there were an estimated 150 million adults with diabetes in 2000 and this is expected to rise to 366 million by 2030. People with type 2 diabetes are twice as likely to have cardiovascular disease than non-diabetics and are also more at risk of microvascular complications (damage to small blood vessels).

Glycaemic lowering therapies are commonly used to treat people with type 2 diabetes to prevent long term cardiovascular complications and renal and visual impairment, but previous studies have not shown clear and universal benefits of the treatment.

So a team, led by Catherine Cornu at the Louis Pradel Hospital in Bron, France, reviewed studies that looked at microvascular complications and cardiovascular events related to the intensity of glycaemic control and the quality of trials.

They analysed 13 studies involving 34,533 patients of whom 18,315 were given intensive glucose lowering treatment and 16,218 given standard treatment.

They found that intensive glucose treatment did not significantly affect all-cause mortality or cardiovascular death.

There was, however, a 15% reduction in the risk of non-fatal heart attacks, following intensive treatment and a 10% reduction in microalbuminuria -- an indication of kidney problems and heart disease -- but a more than two-fold increase in the risk of severe hypoglycaemia (dangerously low blood glucose levels).

The researchers calculated that over a five-year treatment period, 117 to 150 patients would need to be treated to avoid one heart attack, 32 to 142 to avoid one case of microalbuminuria, and 15 to 52 to avoid one severe hypoglycaemic event.

They conclude: "Intensive glucose lowering treatment of type 2 diabetes should be considered with caution and therapeutic escalation should be limited."

In an accompanying editorial, UK experts state that clinicians should consider the absolute risks and benefits of more intensive therapy carefully on an individual patient basis to determine the most sensible treatment strategy.

Email or share this story:

Tuesday, August 16, 2011

Test measuring blood glucose control may help predict risk of CVD events in patients with diabetes

ScienceDaily (July 25, 2011) — Measuring hemoglobin A 1c (HbA 1c ) levels in patients with diabetes is associated with improvement in models for predicting risk for cardiovascular disease (CVD), according to a report published Online First on July 25 by Archives of Internal Medicine, one of the JAMA/Archives journals.See Also:Health & MedicineDiabetesCholesterolWounds and HealingAsthmaMultiple Sclerosis ResearchDiseases and ConditionsReferenceDiabetic dietBlood sugarDiabetes mellitus type 2Hyperglycemia

According to background information in the article, diabetes has been recognized as a risk factor for CVD. But recent research indicates that the level of risk may vary among patients with diabetes. "Simulated cost-benefit analyses have suggested that this variability in CVD risk could provide an opportunity for tailored preventive therapy in diabetic patients," write the authors. They sought to investigate the predictive value of HbA 1c levels; this test reflects the average blood glucose level over the previous two to three months, and generally indicates how well the diabetes is being managed.

Nina P. Paynter, Ph.D., from Brigham and Women's Hospital, Boston, and colleagues, used data from participants of the Women's Health Study and the Physician's Health Study II. To generate the model, they included data from 24,674 women, of whom 685 had diabetes at baseline, and 11,280 men, of whom 563 had diabetes at baseline. Questionnaires provided participants' health history, and baseline blood samples were evaluated for cholesterol, C-reactive protein and HbA 1c levels. The researchers followed up participants for incident (new cases) CVD; women were followed up for a median (midpoint) of 10.2 years and men for a median of 11.8 years.

During follow-up, 125 cardiovascular events occurred in the 685 women with diabetes and 170 events occurred in the 563 men with diabetes (compared with 666 and 1,382 events, respectively, in participants without diabetes). In both sexes, including HbA 1c into risk modeling for CVD improved prediction of CVD compared to classification of all diabetic participants as high risk (10-year risk at least 20 percent). This association was especially pronounced in women. The risk modeling demonstrated that 71.9 percent of female diabetic participants had less than a 20 percent risk of CVD over 10 years, whereas only 24.5 percent of male diabetic participants had a predicted 10-year CVD risk of less than 20 percent. In models that included a term for HbA 1c , there was substantial improvement in CVD risk prediction for women, and more modest improvement in risk prediction for men. Using a yes/no term for diabetes instead of HbA 1c also improved prediction over classification as high risk in both men and women. In women, however, HbA 1c further improved prediction over the yes/no term.

"We found that in these large population-based cohorts of both men and women, presence of diabetes alone did not confer a 10-year risk of CVD higher than 20 percent, and measurement of HbA 1c level in diabetic subjects improved risk prediction compared with classification as cardiovascular risk equivalent," note the researchers. They propose that the difference in risk between the sexes may be partly attributed to the increase in CVD risk with age and the delayed risk in women. The authors call for further research to replicate their results, but conclude, "Our findings suggest that the improvement in CVD risk prediction, and possibly calibration, obtained with adding HbA 1c levels is highest in lower-risk populations."

This work was carried out with support from F. Hoffmann-La Roche Ltd; and grants from the National Heart Lung and Blood Institute, the National Cancer Institute and the Donald W. Reynolds Foundation, Las Vegas.


Commentary: Cardiovascular Risk Stratification, Hemoglobin A 1c , and the Tempo of Translation

An accompanying commentary by Mark J. Pletcher, M.D., M.P.H., from the University of California, San Francisco, notes that the Adult Treatment Panel III (ATP III) guidelines and other cardiovascular disease (CVD) prevention guidelines will be updated soon.

"One specific guideline refinement up for consideration this year is the approach to CVD risk stratification in patients with diabetes," writes Pletcher. He states that under current ATP III guidelines, diabetes is considered a "CHD

Monday, August 15, 2011

Studies evaluate programs to transition care of patients after hospital discharge

ScienceDaily (July 25, 2011) — Programs designed to help transition care for hospitalized older patients to outside healthcare clinicians and settings are associated with reduced rates of hospital readmissions, according to two reports in the July 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.See Also:Health & MedicineToday's HealthcareHealth PolicyWounds and HealingScience & SocietyPublic HealthWorld DevelopmentBioethicsReferenceClinical trialEvidence-based medicineDouble blindPalliative care

"In the United States, 30-day all-cause readmission rates for patients 65 years or older generally range from 20 percent to 25 percent, depending on clinical condition and geographic region, indicating much room for improvement," the authors write as background information in one of the articles. "Interventions addressing patient- and systems-level factors show promise for reducing hospital readmissions."

In the first article, Rachel Voss, M.P.H., of Quality Partners of Rhode Island, Providence, and colleagues examined the effects of the Care Transitions Intervention randomized controlled trial in a real-world setting to test its effectiveness in reducing hospital readmissions. The intervention occurred over a period of 30 days and included a coach who completed a hospital visit, a home visit and two follow-up telephone calls with the patient.

Between January 2009 and June 2010, the authors recruited patients at six Rhode Island acute care hospitals for participation in the intervention. Patients were separated into three groups: intervention group, internal control group (patients were approached but declined the intervention or did not complete the home visit) and external control group (patients not approached but eligible for participation based on study criteria).

Of the 1,888 patients approached for the study, 1,042 (55.2 percent) agreed to participate and of those, 257 (24.7 percent; 13.6 percent of the eligible participation group) completed the full intervention with home visit. The odds of hospital readmission within 30 days of discharge were significantly lower for patients participating in the intervention compared with those who were never approached for participation (12.8 percent readmission rate vs. 20 percent readmission rate). Individuals in the internal control group had readmission rates similar to those of the external control group (18.6 percent). The authors conclude that, "the Care Transitions Intervention appears to be effective in this real-world implementation. This finding underscores the opportunity to improve health outcomes beginning at the time of discharge in open health care settings."

In a second article, Brett D. Stauffer, M.D., M.H.S., of the Institute for Health Care Research and Improvement, Baylor Health Care System, Dallas, evaluated an advanced practice nurse-led transitional care program for patients 65 years and older with heart failure who were discharged from Baylor Medical Center Garland (BMCG) from August 2009 through April 2010. The program included a pre-discharge intervention by the advanced practice nurse and at least eight post-discharge house calls per patient.

The study examined the association between the transitional program and 30-day (from discharge) all-cause readmission rate, length of stay and 60-day (from admission) direct cost for BMCG with that of other hospitals within the Baylor Health Care System.

During the study period, 140 Medicare patients with heart failure were eligible for the intervention and of these, 56 (40 percent) enrolled in the study. The adjusted 30-day readmission rate was 48 percent lower at BMCG after the intervention than before, however the intervention had little effect on hospital length of stay or total 60-day direct costs for the center compared to other hospitals in the Baylor system.

"Preliminary results suggest that transitional care programs reduce 30-day readmission rates for patients with heart failure," the authors conclude. "This underscores the potential of the intervention to be effective in a real-world setting, but payment reform may be required for the intervention to be financially sustainable by hospitals."

Editorial: Interventions to Decrease Hospital Readmission Rates

"Decreasing hospital readmissions offers the hope of improving care while simultaneously reducing health care costs," writes Mitchell H. Katz, M.D., of the Los Angeles County Department of Health Services. "It is therefore comforting to read in this issue of the Archives about two successful real-world translations of interventions shown to be effective in reducing hospitalizations in RCTs."

However, Dr. Katz also notes that, "Although it is pleasing to see the results of the prior interventions extended, other aspects of these real-world trials are sobering." He points to the low participation rate in the Voss et al study, as well as the limited financial benefit found in the Stauffer et al study. "The cost-analysis by Stauffer et al points to a widespread problem in American medicine," he writes. "Reimbursements are generally linked to episodes of care: visits, hospitalizations, treatments and procedures. Reimbursements are rarely provided for preventing negative outcomes."

"We need to pay for quality not quantity, for preventing illness not just treating it," Dr. Katz concludes. "Global payments with quality incentives are needed to improve America's health care system and reduce its cost."

Email or share this story:

Sunday, August 14, 2011

Drug shown to improve sight for patients with inherited blindness

ScienceDaily (July 25, 2011) — A clinical trial led by Newcastle University shows that the drug, idebenone (Catena®), improved the vision and perception of colour in patients with Leber's Hereditary Optic Neuropathy (LHON). The inherited condition means patients, who can see normally, lose the sight in one eye then within 3 to 6 months lose the sight in their other eye.See Also:Health & MedicineEye CareToday's HealthcareDiseases and ConditionsBirth DefectsPharmacologyMultiple Sclerosis ResearchReferenceClinical trialDouble blindPeripheral visionVisual acuity

In some severely affected patients such as those who were unable to read any letters on the chart, the treatment with idebenone resulted in a marked improvement in their vision. In nine patients (12 eyes) out of 36 patients (61 eyes) taking idebenone, vision improved to the extent that patients were able to read at least one row of letters on the chart. In contrast not a single patient of the 26 who were taking the placebo improved to that extent.

Inherited from the mother, and mainly affecting men, LHON is caused by damage to the mitochondria in the eyes -- the 'batteries' which power their cells. It is one of the most common causes of inherited blindness and is thought to affect around 2,000 people in the UK, around 10,000 in Europe and a further 10,000 in the USA.

"This is the first proven treatment for a mitochondrial disorder. We have seen patients who couldn't even see an eye chart on the wall go on to read the first line down -- and some even attempted the second line. For these patients, it can mean a vast improvement in their quality of life," said Professor Patrick Chinnery, a Wellcome Trust Senior Fellow in Clinical Science at Newcastle University who also works at the Royal Victoria Infirmary in Newcastle -- part of the Newcastle upon Tyne Hospitals NHS Foundation Trust.

Released July 25 in the journal Brain, the authors describe how patients with LHON were recruited from Newcastle Hospitals in the UK, in Munich, Germany and in Montreal, Canada for a double blind trial. Patients were either given idebenone for 24 weeks or a placebo.

At the end of the six months, some patients who were taking idebenone had improved vision and this is the first time a successful treatment has been found. The greatest improvement was seen in patients who had deteriorated in one eye more than the other.

Professor Chinnery explained: "We saw most progress in people who had better vision in one eye than the other -- this tends to indicate that they are at an earlier stage of the condition. While we know that their vision is not what it once was, we also know that this treatment can dramatically improve their lives -- some were able to move around more easily or even see family photos again."

Idebenone penetrates into the mitochondria and is thought to mop-up toxic free radicals and enhance mitochondrial function. Previous research had provided anecdotal reports of improvements in vision but this is the first time it had been put to the test in a clinical trial. The drug company which sponsored this trial, Santhera Pharmaceuticals, is now seeking marketing approval from the European Medicines Agency for it to be offered as a standard form of treatment.

"We are hearing from patients that they still have improved vision -- even though they are no longer taking the drug but we would like to verify this and study the effect further," said Professor Chinnery. "There may also be a case for offering idebenone from the first moment that LHON is diagnosed -- preferably before any symptoms are shown -- and a further trial would ideally examine this."

"I lost the sight in my left eye in just five days"

Mike Scholes, 58 from Lindfield in West Sussex, UK and a graduate of Newcastle University took part in the trial. He said: "I was training for a freefall parachute jump five years ago when I noticed I was having problems with my eye. I went for an eye test at the optician and on the way to pick up my glasses five days later, I nearly crashed the car. The optician tested my right eye and there was no problem, when he came to the left eye I asked him to switch on the machine -- and he said he already had. I had lost the sight in my left eye in just five days.

"This meant an abrupt change in my life -- I had a very successful hot air balloon business and I had to stop flying. I had to sell my cars as I could no longer drive.

"Following seven months of tests including CAT scans, X-Rays, MRI scans and a lumbar puncture, I was finally given a DNA test which revealed I had Leber's hereditary optic neuropathy.

"It was around this time that my vision started to go in my second eye. I couldn't see in an increasingly large area in the centre of my eyes and gradually colours disappeared. At worst the only colours I could make out were shades of blue.

"Soon after friends spotted a clinical trial in Newcastle, I volunteered to take part and started taking the tablets three times a day -- not knowing whether I was taking a placebo or the drug.

"After just a month and a half I noticed that the area affected in the centre of my vision was smaller. The improvement continued and I began to appreciate colours again seeing yellow and most reds.

"Having Leber's hasn't stopped me enjoying life to the full -- I run marathons with a guide, I've hiked to the North pole -- but the noticeable improvement in my vision means daily life is easier. I can use a computerised viewer to help me read, I can get dressed without having to use a detector for the colours of clothes and while initially I couldn't even see the eye chart, now if I get really close to a street sign I can read it."

Email or share this story:

Friday, August 12, 2011

Health-care reform must involve psychologists, medical providers, educate patients, expert says

ScienceDaily (July 21, 2011) — While some members of the U.S. Congress and others are trying to repeal the healthcare reform law that was passed in 2010, known as the "Patient Protection and Affordable Care Act," medical providers have begun to implement requirements as the law slowly phases in over the next several years. For reform to be successful, one University of Missouri public health expert has determined that professional associations for psychologists and other medical providers need to be at the forefront of the planning stages, and that everyone, including providers and patients, will need to be educated on rights and responsibilities.See Also:Health & MedicineToday's HealthcareHealth PolicyMind & BrainMental HealthChild DevelopmentScience & SocietyPublic HealthPrivacy IssuesReferenceAthletic trainingPsychologistPhysical therapyPhysical trauma

"We looked at psychology departments here in the United States and in other countries to determine what worked best when implementing the policies outlined in healthcare reform," said Nancy Cheak-Zamora, assistant professor of health science in the MU School of Health Professions. "Many providers, especially psychologists, work independently, but the new healthcare law is encouraging providers to develop a medical team approach, one that can tackle many different aspects of a disease."

The new law encourages providers to bundle payment methods, study best practices, and develop accountable care organizations (ACO), which are formal groups or institutions that include teams of general practitioners and specialists taking a team approach to patient care. ACOs will have a financial stake in the outcomes of their patients. These changes could force a major shift in health care providers' practices, including those in psychology and rehabilitation. Physicians and psychologists, and specifically rehabilitation psychologists, need to move away from the traditional model of considering mental and behavioral health care services as separate from medical care, Cheak-Zamora said.

Cheak-Zamora said that large professional organizations, such as the American Psychological Association, should take the lead to help form expectations and policies for the team approach. Simultaneously, new psychologists should be trained to work in a team with other medical providers. Benefits of a medical team include reduced unnecessary procedures, less paperwork, better coordination with other providers and specialists, and better monitoring of prescriptions to discourage abuse or unintended drug interaction.

In her analysis, which is being published as a chapter in The Oxford Handbook of Rehabilitation Psychology by Oxford University Press, Cheak-Zamora also found that patients and providers need to be educated about the current system, how to access care, how to get questions addressed, and how to get the quality care patients deserve.

"With the implementation of healthcare reform, many patients might have been uninsured or underinsured for so long that they no longer know how the system is supposed to benefit them," Cheak-Zamora said. "They need to know how to access insurance information and utilize the system effectively."

Additionally, medical staff will need to be trained to handle requests through the new system, and how to work with individuals that do not have experience with insurance.

"Healthcare reform is an outline of what the government wants. Policymakers are working to develop policies, so now is the time to air any concerns and help shape a policy that works for everyone," she said.

Email or share this story:

Friday, August 5, 2011

Patients who used mail-order pharmacy for new statin prescriptions achieved better cholesterol control, study finds

ScienceDaily (July 21, 2011) — Kaiser Permanente Northern California patients who obtained new statin prescriptions via a mail-order pharmacy achieved better cholesterol control in the first 3-15 months following the initiation of therapy -- compared to those patients who only obtained their statin prescription from their local Kaiser Permanente Northern California pharmacy.See Also:Health & MedicinePharmacologyToday's HealthcareCholesterolDiseases and ConditionsWounds and HealingDiabetesReferencePharmacologyPediatricsCOX-2 inhibitorHypercholesterolemia

Greater adjusted rates of LDL-C control in mail-order pharmacy users were seen across all gender and race-ethnicity groups, according to the study that appears in the current online issue of the Journal of General Internal Medicine.

After adjustment for demographic, clinical, and socioeconomic characteristics, as well as for potential unmeasured differences between mail-order and in-person pharmacy users, 85 percent of patients who used the mail-order pharmacy achieved target cholesterol levels, compared to 74.2 percent of patients who only used the local Kaiser Permanente pharmacy.

Previous studies have shown that mail-order pharmacy use is associated with greater medication adherence. However, this is the first study to examine whether mail-order pharmacy use is related to improved cardiovascular risk factor outcomes, according to Julie Schmittdiel, PhD, an investigator with the Kaiser Permanente Division of Research in Oakland, Calif., and the lead author of the study.

"While the findings of this study should be confirmed in a randomized controlled trial, they provide new evidence that mail-order pharmacy use may be associated with improved care and outcomes for patients for risk factors with cardiovascular disease," Schmittdiel said.

"Though mail order may not be right for all patients, this study shows that it is one possible tool in the broader health care system-level toolbox that can help patients meet their medication needs."

At Kaiser Permanente, members have 24/7 access to online pharmacy and pharmacy refills at kp.org using My Health Manager, which can be mailed to them free of shipping charges or made available for pick-up at any Kaiser Permanente pharmacy.

In comparing the effectiveness of mail-order pharmacy vs. local pharmacy use on cholesterol control in new statin users, investigators tapped a study population of 100,298 Kaiser Permanente members who were statin users between Jan. 1, 2005, and Dec. 31, 2007. Statin use was obtained from automated pharmacy records and patients were considered to be new users if they had not recorded use of statin in records prior to the initial statin prescription date.

Greater adherence to these medications by mail-order pharmacy users may reflect improved access to medications, researchers explain. Mail order does not require travel to the local pharmacy, which may provide ease and convenience for patients refilling medications. To address possible selection biases -- for example, the possibility that patients who use mail-order pharmacy services are more motivated to take care of their health than patients who do not use such services -- researchers conducted additional analyses.to minimize such biases. All analyses, even those accounting for such potential differences, showed a positive, significant association between mail order pharmacy use and cholesterol control.

This study is part of an ongoing body of work analyzing the impact of mail-order pharmacy use on clinical outcomes, and seeks to further understand how health care systems can work with patients to optimize medication use without compromising patient choice or safety.

In a January 2010 study in the American Journal of Managed Care, researchers from UCLA and the Kaiser Permanente Division of Research found that patients with diabetes, high blood pressure or high cholesterol who ordered their medications by mail were more likely to take them as prescribed by their doctors than did patients who obtained them from the local pharmacy.

Additional authors on the Journal of General Internal Medicine study include Andrew J. Karter, PhD; Wendy Dyer, MS; Melissa Parker, MS; and Connie Uratsu, all with the Kaiser Permanente Division of Research. James Chan, PharmD, PhD, with the Kaiser Permanente Pharmacy Outcomes and Research Group, and O.Kenrik Duru, MD, MSHS, with the UCLA David Geffen School of Medicine, also are co-authors. Funding was provided by the Centers for Disease Control and Prevention (Division of Diabetes Translation) and the National Institute of Diabetes and Digestive Kidney Diseases.

Email or share this story: